Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte (INCY) PT Raised to $89 at RBC Capital
February 15, 2019 7:16 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $89.00 (from $81.00) while maintaining a Outperform rating.
The analyst commented, "Coming off of a solid quarter for sales and guidance, we see the potential for some additional appreciation in INCYwith... More
Incyte (INCY) PT Raised to $100 at Raymond James
February 15, 2019 7:10 AM ESTRaymond James analyst Reni Benjamin raised the price target on Incyte (NASDAQ: INCY) to $100.00 (from $85.00) while maintaining a Strong Buy rating following results and guidance.
Benjamin said key takeaways include: 1) The Jakafi franchise remains solid with 2018 sales at $1.39 billion; 2) 2019 guidance is for Jakafi to... More
Incyte (INCY) Misses Q4 EPS by 7c
February 14, 2019 7:04 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of $0.40, $0.07 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $468 million versus the consensus estimate of $485.8 million.
2019 Financial... More
